A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

Summary

In this prospective, phase 2b, multicenter, randomized, double-masked, vehicle-controlled, parallel-arm study, approximately 880 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or vehicle as topical ophthalmic eye drops administered bilaterally BID. The study will comprise two phases: a two-week screening phase/run-in and a six-week double-masked treatment phase.

Timeline

Start

2024-02-06

Primary completion

2024-12

Completion

2024-12

Drugs

Indications